
Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Novel Machine Learning Model Improves MASLD Detection in Type 2 Diabetes
2
Real-World Data Highlight Value of NOTCH1 Screening in CLL
3
Accountable Care: Not Just for the Healthiest Patients
4
Emerging Therapies for Managing Hidradenitis Suppurativa in Patients With Skin of Color
5